Introduction
Copper chelation is the established treatment of Wilson's disease. Primary biliary cirrhosis (PBC) is associated with high liver copper concentrations (Hunt et al., 1963) and assessment of D-penicillamine therapy is under trial. Early results are encouraging and indicate that life expectancy may be prolonged by treatment (Dickson et al., 1977) , but side effects are more frequent than in the treatment of Wilson's disease, and the drug has had to be withdrawn in 26% of patients (Jain et al., 1977) . A case of erythromyeloid aplasia induced by D-penicillamine therapy is now reported.
Case report A diagnosis of PBC was made in a 34-year-old woman after a one-month history of right upper quadrant pain. She had been pigmented for 2 years and had hepatomegaly, splenomegaly, raised serum alkaline phosphatase (518-4 i.u./l, normal 20-95 i.u./l) high titre serum mitochondrial antibodies and a liver biopsy compatible with late PBC. Liver copper concentration was 9 5 ,umol/g dry liver (normal less than 0'9 [Lmol/g). Haemoglobin (Hb) 
Discussion
Initiation of D-penicillamine therapy is frequently followed by moderate degrees of thrombocytopenia, neutropenia and taste impairment, although rarely severe enough to warrant withdrawal of treatment. Skin eruptions, particularly urticaria, are also common, but de-sensitization can usually be achieved by re-introduction of n-penicillamine with a short course of corticosteroid drugs (Walshe, 1963) .
Total marrow aplasia is a well recognized complication of D-penicillamine therapy in rheumatoid arthritis (Bourke et al., 1976) . Agranulocytosis, though rare, is more common in the first year of therapy and is usually reversible on stopping the drug (Golding, Wilson and Day, 1970) . Selective red cell aplasia has occurred after prolonged treatment of a patient with Wilson's disease with Dpenicillamine (Gollan et al., 1976) . The occurrence of erythro-myeloid aplasia with preservation of platelet production confirms that D-penicillamineinduced blood dyscrasias can selectively involve any of the haemopoietic cell lines. The mechanism of action is not known, but appears to be idiosyncratic rather than cytotoxic.
Granulocyte transfusions have been used in the treatment of granulopenic patients with infections (Vallejos, McCredie and Bodley, 1975) , and the cells can be conveniently obtained as a by-product from the preparation of platelet transfusions. In a randomized trial in granulopenic patients with Gram-negative septicaemia, the transfusions were shown to complement the appropriate antibiotic treatment and significantly improve survival (Herzig et al., 1977) . This form of treatment should therefore be considered in the treatment of septicaemia in patients with granulopenia. 
